Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, multiple dose
escalation study, enrolling approximately 48 subjects. Part A of the study will enroll
subjects with Systemic Lupus Erythematosus (SLE) without Glomerulonephritis (GN) into 3
cohorts. Part B of the study will enroll SLE subjects with GN into 3 cohorts. The purpose of
the study is to evaluate the multiple dose of AMG 811 on safety. Tolerability and
pharmacokinetics.